[Skip to Content]
[Skip to Content Landing]
Views 2,038
Citations 0
Editorial
March 3, 2020

Lobbying Expenditures, Campaign Contributions, and Health Care—Follow the Money

Author Affiliations
  • 1Editor at Large, JAMA Internal Medicine
JAMA Intern Med. Published online March 3, 2020. doi:10.1001/jamainternmed.2020.0145

All the President’s Men, the 1976 film about the Watergate scandal, popularized the phrase “follow the money” as a way to connect the dots between expenditures and outcomes in politics and government. Although the money trail is often informative, it may not provide convincing evidence about the influence of cash on specific election, legislative, and policy outcomes. Nonetheless, it is impossible to understand the influence of industry and interest groups on US health policy without considering the breathtaking sums these organizations spend for lobbying and contributions to political campaigns. The goals are to influence both who gets elected and what they do when they are in office. Not only are the sums large, but they also dwarf the spending of groups representing the interests of patients and consumers. Moreover, industry funding of patient groups is common in the US and other high-income countries, although the corporate support may not be transparent.1

In this issue of JAMA Internal Medicine, Wouters2 reports on lobbying expenditures and campaign contributions by the pharmaceutical and health product industry in the US from 1999 to 2018. The pharmaceutical and health product industry is part of the health sector of the economy, which also includes health care professionals, hospitals, nursing homes, and other patient care organizations. Health insurance companies are classified in the insurance industry.

Among all industries, the study found that the pharmaceutical and health product industry ranked first for federal-level lobbying expenditures—accounting for $4.7 billion of $64.3 billion (7.3%) of all spending over the 20-year period, with no other industry accounting for more than 5%.2 Other notable findings were the average of $233 million per year in lobbying expenditures, the $414 million in contributions over 20 years to candidates and other groups for presidential and congressional elections, and the average of $44 million per year in contributions to state candidates and committees, often related to ballot measures about the costs of prescription drugs.2

Within the industry, the trade group Pharmaceutical Research and Manufacturers of America (PhRMA) and large drug companies were the highest spending organizations, accounting for 17 of the top 20 organizations for lobbying expenditures and 16 of the top 20 for federal campaign contributions. PhRMA ranked first for lobbying spending, with annual expenditures averaging $21.1 million, and 14th for campaign contributions; 5 pharmaceutical companies were among the top 10 spenders in both categories. The medical device trade group Advanced Medical Technology Association ranked 15th for lobbying expenditures, and the medical device company Medtronic ranked 17th. Across all industries over 20 years, PhRMA’s lobbying expenditures ranked sixth, with the American Medical Association (AMA) and the American Hospital Association (AHA) ranked third and fourth, respectively.2

The study by Wouters2 follows articles I wrote on campaign contributions, lobbying, and the US health sector in the 2000s.3-5 Little has changed, with industries and organizations in the health sector continuing to spend substantial sums to influence the outcomes of elections, legislation, and regulations.

One reason why PhRMA and large pharmaceutical companies have both the money and the motivation to spend on lobbying and campaign contributions is the extraordinary profitability of the drug industry in the US. In JAMA, Ledley and colleagues6 report that between 2000 and 2018, the profitability of large pharmaceutical companies was significantly greater than the profitability of other large, public companies, although the differences were less pronounced when factors such as company size, year, and research and development expenses were taken into account. From a business perspective, the lobbying expenditures in the pharmaceutical and health product industry appear to be money well spent.

A decade ago, the focus of federal lobbying and campaign contributions for the US health sector was health care reform. In 2010, President Obama signed the Patient Protection and Affordable Care Act into law. Although Wouters2 found that the pharmaceutical and health product industry donated more money overall to Republican candidates and national party committees than to Democratic candidates and committees ($216 million vs $151 million; 58.9% vs 41.1%), the Democrats received more money in the 2008 election cycle (2007-2008), when President Obama was elected, and the 2010 election cycle (2009-2010), during which the Democrats held majorities in both the House of Representatives and the Senate.2 Both parties are major beneficiaries of this industry largesse.

Also in 2010, the Supreme Court ruling in Citizens United v Federal Election Commission7 legalized campaign contributions to outside spending groups, including those by corporations and nonprofit organizations. Subsequently, there has been little traction for either substantive federal campaign finance or lobbying reforms. For example, Wouters2 found that the 2016 election cycle (2015-2016), which included the presidential election contest between Hillary Clinton and Donald Trump, had the highest spending on campaign contributions by the pharmaceutical and health product industry. And in 2019, the $3.4 billion overall amount spent on federal lobbying was the most since 2010.8

In 2019 and again in 2020, the affordability of insulin and other prescription drugs and surprise medical bills are 2 of the most contentious health policy issues in the US.9,10 Bringing a new drug to market is expensive, although it is difficult to assess the research and development costs because of the limited data in the public domain. In JAMA, a study by Wouters and colleagues11 estimated the median and mean capitalized research and development investments for new therapeutic agents between 2009 and 2018 at $985 million and $1336 million, respectively. In another study in JAMA, Hernandez and colleagues12 report that between 2007 and 2018, the mean list and net prices of branded drugs in the US increased substantially, although discounts partially offset the list price increases. Studies have repeatedly shown how the federal government could decrease Medicare spending for prescription drugs through means such as using the US Department of Veterans Affairs medication prices,13 generic substitution and therapeutic interchange,14 or negotiated prices and a defined formulary.9,15 Such reforms, which should decrease costs to both the federal government and patients, have not occurred.

In 2019, in response to the calls for drug pricing reform, PhRMA spent a record $28.9 million lobbying Congress and federal agencies, surpassing its previous record of $27.5 million set in 2018 and considerably more than either the AHA ($22.2 million) or the AMA ($20.0 million) spent on federal lobbying, although the AHA and the AMA also increased their spending.8 Together, PhRMA and the major pharmaceutical companies that belong to the trade group spent more than $120 million lobbying Congress in 2019.16 On the surprise medical bills issue, hospitals and physicians have lobbied Congress to protect their reimbursements. Notably, 4 physician organizations that have taken the lead in lobbying Congress on surprise medical bills have ties to companies backed by private equity.17 As of February 2020, none of the major bills to lower drug prices or to reign in surprise medical bills have been enacted into law, bipartisan support for both reforms notwithstanding. In contrast, Congress in 2019 repealed taxes that were central to the Affordable Care Act, including taxes on expensive health care plans, health insurance companies, and medical device manufacturers.18

Lobbying expenditures and campaign contributions are only 2 of the links between government and the pharmaceutical and health product industry. A third example is industry user fees. In fiscal year 2019, the budget of the US Food and Drug Administration (FDA) is $5.7 billion; federal budget authorization provides about $3.1 billion (55%), and industry user fees pay for the remaining $2.6 billion (45%).19 Industry user fees pay for 65% of regulatory activities for human drugs and pay entirely for the Tobacco Control Act Program.19 The profitability of the pharmaceutical industry facilitates payments of user fees as well as the large settlements between the US Department of Justice and certain drug companies in civil and criminal cases.20 The quid pro quo for these fees is that industry demands faster and faster approval of new drugs, even before they are fully shown to be safe and effective. With user fees providing nearly half of the FDA’s budget, the agency can be perceived as serving the interests of the industry it regulates, not the general interests of the public.

A fourth example is the “revolving door” of personnel, common among Democrats and Republicans, between roles as legislators and regulators and roles in the industries affected by the legislation and regulation. At present, the secretary of the Department of Health and Human Services is a former pharmaceutical lobbyist and drug company executive, and the director of the White House Domestic Policy Council is a former pharmaceutical lobbyist. The first FDA commissioner in the Trump administration has worked with many pharmaceutical companies, including as a venture capitalist and a member of the board of directors of companies, before and after his government tenure.

On November 3, 2020, the US will elect a president, all 435 members of the House of Representatives, and 35 members of the Senate. Voters will consider many issues in addition to health care and the affordability of prescription drugs. The study by Wouters2 informs voters and candidates about lobbying expenditures and campaign contributions by the pharmaceutical and health product industry and adds to factual discussions about whether the current level of industry influence on US health policy is desirable or if now is the time for change.

Back to top
Article Information

Corresponding Author: Robert Steinbrook, MD, JAMA Internal Medicine, Editorial Office, University of California, San Francisco, 505 Parnassus Ave, Ste M1180, PO Box 0124, San Francisco, CA 94143-0124 (robertsteinbrook@gmail.com).

Published Online: March 3, 2020. doi:10.1001/jamainternmed.2020.0145

Conflict of Interest Disclosures: None reported.

References
1.
Fabbri  A, Parker  L, Colombo  C,  et al.  Industry funding of patient and health consumer organisations: systematic review with meta-analysis.  BMJ. 2020;368:l6925. doi:10.1136/bmj.l6925PubMedGoogle ScholarCrossref
2.
Wouters  OJ.  Lobbying expenditures and campaign contributions by the pharmaceutical and health product industry in the United States, 1999-2018  [published online March 3, 2020].  JAMA Intern Med. doi:10.1001/jamainternmed.2020.0146Google Scholar
3.
Steinbrook  R.  Election 2008—campaign contributions, lobbying, and the US health sector.  N Engl J Med. 2007;357(8):736-739. doi:10.1056/NEJMp078151PubMedGoogle ScholarCrossref
4.
Steinbrook  R.  Campaign contributions, lobbying, and the US health sector—an update.  N Engl J Med. 2008;359(13):1313-1315. doi:10.1056/NEJMp0807073PubMedGoogle ScholarCrossref
5.
Steinbrook  R.  Lobbying, campaign contributions, and health care reform.  N Engl J Med. 2009;361(23):e52. doi:10.1056/NEJMp0910879PubMedGoogle Scholar
6.
Ledley  FD, McCoy  SS, Vaughan  G, Cleary  EK.  Profitability of large pharmaceutical companies compared with other large public companies  [published online March 3, 2020].  JAMA. doi:10.1001/jama.2020.0442Google Scholar
7.
Citizens United v Federal Election Commission, 558 US 310 (2010).
8.
Wilson  MR. Lobbying spending in 2019 reached second highest point of decade. Accessed February 11, 2020. https://about.bgov.com/news/lobbying-spending-in-2019-reached-second-highest-point-of-decade
9.
Feldman  WB, Rome  BN, Lehmann  LS, Kesselheim  AS.  Estimation of Medicare Part D spending on insulin for patients with diabetes using negotiated prices and a defined formulary  [published online February 3, 2020].  JAMA Intern Med. doi:10.1001/jamainternmed.2019.7018PubMedGoogle Scholar
10.
Steinbrook  R.  Ending surprise medical bills.  JAMA Intern Med. 2019;179(11):1465-1466. doi:10.1001/jamainternmed.2019.3382PubMedGoogle ScholarCrossref
11.
Wouters  OJ, McKee  M, Luyten  J.  Estimated research and development investment needed to bring a new medicine to market, 2009-2018  [published online March 3, 2020].  JAMA. doi:10.1001/jama.2020.1166Google Scholar
12.
Hernandez  I, San-Juan-Rodriguez  A, Good  CB, Gellad  WF.  Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018  [published online March 3, 2020].  JAMA. doi:10.1001/jama.2020.1012Google Scholar
13.
Venker  B, Stephenson  KB, Gellad  WF.  Assessment of spending in Medicare Part D if medication prices from the Department of Veterans Affairs were used.  JAMA Intern Med. 2019;179(3):431-433. doi:10.1001/jamainternmed.2018.5874PubMedGoogle ScholarCrossref
14.
Growdon  ME, Sacks  CA, Kesselheim  AS, Avorn  J.  Potential Medicare savings from generic substitution and therapeutic interchange of ACE inhibitors and angiotensin-II-receptor blockers.  JAMA Intern Med. 2019;179(12):1712-1714. doi:10.1001/jamainternmed.2019.3107PubMedGoogle ScholarCrossref
15.
Feldman  WB, Avorn  J, Kesselheim  AS.  Potential Medicare savings on inhaler prescriptions through the use of negotiated prices and a defined formulary  [published online December 2, 2019].  JAMA Intern Med. doi:10.1001/jamainternmed.2019.5337PubMedGoogle Scholar
16.
Florko  N. Want to know how contentious drug pricing is in Washington? Check the receipts. Accessed February 6, 2020. https://www.statnews.com/2020/01/23/lobbying-drug-pricing-receipts/
17.
Pradhan  R. When your doctor is also a lobbyist: inside the war over surprise medical bills. Kaiser Health News. February 12, 2020. Accessed February 18, 2020. https://khn.org/news/when-your-doctor-is-also-a-lobbyist-inside-the-war-over-surprise-medical-bills/
18.
Stein  J, Abutaleb  Y. Congress showers health care industry with multibillion-dollar victory after wagging finger at it for much of 2019. Washington Post. December 20, 2019. Accessed February 11, 2020. https://www.washingtonpost.com/business/economy/congress-showers-health-care-industry-with-multi-billion-victory-after-wagging-finger-at-it-for-much-of-2019/2019/12/19/9422aa6a-2028-11ea-9146-6c3a3ab1be6c_story.html
19.
US Food and Drug Administration. FDA at a glance. October 2019. Accessed February 11, 2020. https://www.fda.gov/media/131874/download
20.
Wikipedia. List of largest pharmaceutical settlements. Accessed February 11, 2020. https://en.wikipedia.org/wiki/List_of_largest_pharmaceutical_settlements
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×